With the high incidence of neurological diseases such as stroke and mental illness, rehabilitation treatments for neurological disorders have received widespread attention. Electroencephalography (EEG) technology, despite its excellent temporal resolution, has historically been limited in application due to its insufficient spatial resolution, and is mainly confined to preoperative assessment, intraoperative monitoring, and epilepsy detection. However, traditional constraints of EEG technology are being overcome with the popularization of EEG technology with high-density over 64-lead, the application of innovative analysis techniques and the integration of multimodal techniques, which are significantly broadening its applications in clinical settings. These advancements have not only reinforced the irreplaceable role of EEG technology in neurorehabilitation assessment, but also expanded its therapeutic potential through its combined use with technologies such as transcranial magnetic stimulation, transcranial electrical stimulation and brain-computer interfaces. This article reviewed the applications, advancements, and future prospects of EEG technology in neurorehabilitation assessment and treatment. Advancements in technology and interdisciplinary collaboration are expected to drive new applications and innovations in EEG technology within the neurorehabilitation field, providing patients with more precise and personalized rehabilitation strategies.
ObjectiveTo investigate the effect of the interval between neoadjuvant chemoradiotherapy (nCRT) and surgery on the clinical outcome of esophageal cancer.MethodsPubMed and EMbase databases from inception to March 2018 were retrieved by computer. A random-effect model was used for all meta-analyses irrespective of heterogeneity. The meta-analysis was performed by RevMan5.3 software. The primary outcomes were operative mortality, incidence of anastomotic leakage, and overall survival; secondary outcomes were pathologic complete remission rate, R0 resection rate, and positive resection margin rate.ResultsA total of 17 studies with 18 173 patients were included. Among them, 13 were original studies with 2 950 patients, and 4 were database-based studies with a total of 15 223 patients. The results showed a significant positive correlation between the interval and operative mortality (Spearman coefficient=0.360, P=0.027). Dose-response meta-analysis revealed that there was a relatively better time window for surgery after nCRT. Further analysis for primary outcomes at different time cut-offs found the following results: (1) when the time cut-off point within 30-70 days, the shorter interval was associated with a reduced operative mortality (7-8 weeks: RR=0.67, 95% CI 0.55-0.81, P<0.05; 30-46 days: RR=0.63, 95%CI 0.47-0.85, P<0.05; 60-70 days: RR=0.64, 95%CI 0.48-0.85, P<0.05); (2) when the time cut-off point within 30-46 days, the shorter interval correlated with a reduced incidence of anastomotic leakage (RR=0.39, 95%CI 0.21-0.72, P<0.05); when the time cut-off point within 7-8 weeks, the shorter interval could achieve a critical-level effect of reducing the incidence of anastomotic leakage (RR=0.73, 95%CI 0.52-1.03, P>0.05); (3) when the time cut-off point within 7-8 weeks, increased interval significantly was associated with the poor overall survival (HR=1.17, 95% CI 1.00-1.36, P<0.05). Secondary outcomes found that the shorter interval could significantly reduce the positive resection margin rate (RR=0.53, 95% CI 0.38-0.75, P<0.05) when time cut-off point within 56-60 days.ConclusionShortening the interval between nCRT and surgery can reduce the operative mortality, the incidence of anastomotic leakage, long-term mortality risk, and positive resection margin rate. It is recommended that surgery should be performed as soon as possible after the patient's physical recovery, preferably no more than 7-8 weeks, which supports the current study recommendation (within 3-8 weeks after nCRT).
【摘要】 目的 比較舒芬太尼與等效劑量芬太尼在髖關節置換術后患者硬膜外鎮痛的臨床效果。 方法 2006年11月-2008年9月收治的50例硬膜外麻醉下髖關節置換術患者，隨機分為兩組（n=25）。芬太尼組（A組）:芬太尼0.75 mg加0.894%甲磺酸哌卡因20 mL加生理鹽水至100 mL；舒芬太尼組（B組），舒芬太尼75 μg加0.894%甲磺酸哌卡因20 mL加生理鹽水至100 mL硬膜外鎮痛。其中，A組患者于手術結束時，靜脈滴注格拉司瓊3 mg。持續劑量2 mL/h，單次給藥量（PCA）0.5 mL/次，鎖定時間15 min。觀察兩組的鎮痛效果，惡心、嘔吐次數，記錄脈搏血氧飽和度、心率、呼吸的變化。 結果 鎮痛泵開機后，B組各時段鎮靜評分，2分以上者明顯多于A組，鎮痛評分明顯低于A組，有統計學意義（Plt;0.05），兩組術后惡心、嘔吐發生率都較低，組間差異無統計學意義（Pgt;0.05）。兩組4、12、24 h的呼吸頻率和脈搏血氧飽和度差異有統計學意義（Plt;0.05），但48 h的呼吸頻率和脈搏血氧飽和度無統計學意義（Pgt;0.05）。 結論 在等效劑量下，髖關節置換術后患者硬膜外鎮痛，舒芬太尼明顯優于芬太尼。【Abstract】 Objective To compare the clinical effect of epidural analgesia with sufentanil and fentanyl in an equivalent dose after hip replacement. Methods From December 2006 to September 2008, fifty cases of epidural anesthesia after hip replacement were randomly divided into two groups, each group had 25 cases. Group A (fentanyl group): fentanyl mesylate 0.75 mg+0.894% ropivacaine 20 mL+0.9% sodium chloride solution to 100 mL; group B (sufentanil group): sufentanil 75 μg+0.894% ropivacaine mesylate 20 mL+0.9% sodium chloride solution to 100 mL epidural analgesia. Patients in group A received intravenous infusion of granisetron 3 mg at the end of surgery. Continuous dose was 2 mL/h, with the volume of single dose (PCA) 0.5 mL per time and lockout time of 15 minutes. The analgesic effect, nausea, and vomiting frequency were observed, and the pulse oxygen saturation, heart rate, and breathing changes were recorded. Results After boot analgesia, S sedation scores for each phase and pain score in group B were significantly different compared with those in group A (Plt;0.05). Both groups had low incidence of nausea and vomiting, and the difference was not statistically significant (Pgt;0.05). The difference of respiratory rate and pulse oxygen saturation at 4 h, 12 h, 24 h was statistically significant between two groups (Plt;0.05), but at 48 h the difference was not significant (Pgt;0.05). Conclusion In the equivalent dose, epidural analgesia with sufentanil in the patients with hip replacement is superior to fentanyl.
